Soler et al. identified that the ratio between CD14+ blood cells with low levels or no HLA-DR ( HLA-DRneg/low) and those positive for VNN2 (VNN2+) can differentiate patients with recurrent GBM from those with radiation necrosis, highlighting its potential in challenging clinical cases [70]. The gene discussed is VNN2; the disease is glioblastoma.